Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

INTRODUCTION: Oncogenic alterations in RET occur in 1–2% of non-small-cell lung cancers (NSCLCs). The efficacy and safety of the first-in-class, highly selective, and potent RET inhibitor selpercatinib in Chinese patients with RET fusion-positive NSCLC remains unknown. METHODS: In this open-label, m...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Cheng, Ying, Huang, Dingzhi, Sun, Yuping, Wu, Lin, Zhou, Chengzhi, Guo, Ye, Shao, Jingxin, Zhang, Wanli, Zhou, Jianying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340421/
https://www.ncbi.nlm.nih.gov/pubmed/35923928
http://dx.doi.org/10.1177/17588359221105020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340421/
https://www.ncbi.nlm.nih.gov/pubmed/35923928
http://dx.doi.org/10.1177/17588359221105020

Ejemplares similares